Autoimmune polyglandular syndrome type 2: a rare condition in childhood.
Autoimmune polyglandular syndrome type 2: a rare condition in childhood. J Clin Res Pediatr Endocrinol. 2015 Mar 5;7(1):80-2 Authors: Kırmızıbekmez H, Yeşiltepe Mutlu RG, Demirkıran Urgancı N, Öner A Abstract Autoimmune polyglandular syndrome type 2 is defined as the occurrence of Addison's disease concomitantly with autoimmune thyroid disease and/or type 1 diabetes mellitus. An 11-year-old boy with Hashimoto's disease, Addison's disease, celiac disease and Langerhans islet cell autoimmunity is described in this case report. Treatment of an endocrine disease may also trigger the onset of another endocrine disease. This case report underlines the importance of early recognition and treatment of critical endocrine diseases as well as the necessity to investigate pediatric patients with autoimmune diseases for coexisting conditions. Furthermore, the role of psychological stress as an inducer of autoimmunity was also discussed. PMID: 25800482 [PubMed - in process]
Infants and toddlers should not be given soda, chocolate milk or other sweetened drinks, according to strict new guidelines.
In this study, the trends of risk factors and macrovascular complications were examined in patients with DM in Taiwan.MethodsHealth care information and International Classification of Diseases, Ninth Revision diagnostic codes were retrieved from the Taiwan Bureau of National Health Insurance claims files between 2005 and 2014. Using these data, the number of cases and annual prevalence of diabetic macrovascular complications in individuals with DM were stratified by age and sex.ResultsThe prevalence of DM with either stroke or cardiovascular disease (CVD) showed a decreasing trend in enrolled patients with DM (p for trend
ConclusionsPreoperative periosteal reaction is a predictor of a poor outcome after surgical treatment for MRONJ. Clinicians should consider complete resection of the bone showing periosteal reaction.
Publication date: October 2019Source: The Lancet Diabetes &Endocrinology, Volume 7, Issue 10Author(s): Shampa Ghosh, Manchala Raghunath, Bhudev Chandra Das, Jitendra Kumar Sinha
Publication date: October 2019Source: The Lancet Diabetes &Endocrinology, Volume 7, Issue 10Author(s): Fiona Conner, Elizabeth Pfiester, James Elliott, Anbreen Slama-Chaudhry
Publication date: Available online 17 September 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): André J Scheen
Publication date: Available online 17 September 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmonSummaryBackgroundExisting guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are...
Publication date: Available online 17 September 2019Source: Molecular and Cellular EndocrinologyAuthor(s): Galyna V. Graham, Andrew McCloskey, Yasser H. Abdel-Wahab, J. Michael Conlon, Peter R. FlattAbstractPeptidase-resistant analogues of GLP-1 peptides from sea lamprey and paddlefish ([D-Ala2]palmitoyl-lamprey GLP-1 and [D-Ala2]palmitoyl-paddlefish GLP-1) produced significant (P ≤ 0.05) and concentration-dependent increases in insulin release from BRIN-BD11 clonal β-cells and from isolated mouse islets. Both analogues retained the ability of the native peptides to activate both the GLP-1 receptor (GLP1R) and ...